Authorized purpose: Second-reader support for radiologists reviewing adult digital AP or PA chest radiographs, with suspected pulmonary nodules in the 6-30 mm range marked for review.
Clinical role
Adjunctive second reader for radiologists; it is not a substitute for professional interpretation.
Images and patients
X-ray/Radiography · Chest/Lung
Key limitation
Keep in mind: The product is adjunctive and cannot replace radiologist review. The cleared input is adult frontal AP/PA digital chest radiography; performance and applicability outside that scope were not established here.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Second-reader support for radiologists reviewing adult digital AP or PA chest radiographs, with suspected pulmonary nodules in the 6-30 mm range marked for review.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/Lung Input: Adult frontal AP or PA chest radiographs acquired on digital radiography systems and received through DICOM.
Who uses it?Intended users: Radiologists and other qualified healthcare professionals interpreting adult digital chest radiographs.
What does the software produce?Output: Marked suspected pulmonary nodules on the processed image, with the original image presented first and the processed image next in the described workflow.
What is its most important limitation?Key limitation: The product is adjunctive and cannot replace radiologist review. The cleared input is adult frontal AP/PA digital chest radiography; performance and applicability outside that scope were not established here.
Clinical takeaway. Clinical role: Second-reader support for radiologists reviewing adult digital AP or PA chest radiographs, with suspected pulmonary nodules in the 6-30 mm range marked for review.
Evidence takeaway. Evidence from the reviewed source record: In the FDA-described standalone test of 2,181 radiographs, sensitivity was 0.8847, specificity was 0.8294 and AUC was 0.8408. In a separate 400-case MRMC study, the FDA table reports AUC improvement from 0.8071 unaided to 0.8583 aided, sensitivity from 0.7975 unaided to 0.8935 aided, and specificity from 0.8235 unaided to 0.8510 aided. These are exact-submission study results and not current family claims.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Second-reader support for radiologists reviewing adult digital AP or PA chest radiographs, with suspected pulmonary nodules in the 6-30 mm range marked for review.
Marked suspected pulmonary nodules on the processed image, with the original image presented first and the processed image next in the described workflow.
The product is adjunctive and cannot replace radiologist review. The cleared input is adult frontal AP/PA digital chest radiography; performance and applicability outside that scope were not established here.
In the FDA-described standalone test of 2,181 radiographs, sensitivity was 0.8847, specificity was 0.8294 and AUC was 0.8408. In a separate 400-case MRMC study, the FDA table reports AUC improvement from 0.8071 unaided to 0.8583 aided, sensitivity from 0.7975 unaided to 0.8935 aided, and specificity from 0.8235 unaided to 0.8510 aided. These are exact-submission study results and not current family claims.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
In the FDA-described standalone test of 2,181 radiographs, sensitivity was 0.8847, specificity was 0.8294 and AUC was 0.8408. In a separate 400-case MRMC study, the FDA table reports AUC improvement from 0.8071 unaided to 0.8583 aided, sensitivity from 0.7975 unaided to 0.8935 aided, and specificity from 0.8235 unaided to 0.8510 aided. These are exact-submission study results and not current family claims.
DesignTwo-session multi-reader multi-case study with sessions at least one month apart
Population400 chest radiographs read by radiologist participants
Scopeexact submission
Tested versionRayvolve LN configuration submitted in K243831
Samplen=400
IndependenceSponsor or vendor study
K243831
FDA table headings report unaided-to-aided improvement: AUC 0.8071 to 0.8583, sensitivity 0.7975 to 0.8935 and specificity 0.8235 to 0.8510. The source-reported confidence intervals are not reproduced here.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Adult frontal AP or PA chest radiographs acquired on digital radiography systems and received through DICOM.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Standalone deep-learning software connected to a local radiology network through a DICOM node and PACS; the processed image is returned as a DICOM image for review.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The FDA summary describes on-premises or cloud-platform deployment connected to the local radiology network, with DICOM-node/PACS interaction.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Marked suspected pulmonary nodules on the processed image, with the original image presented first and the processed image next in the described workflow.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Marked suspected pulmonary nodules on the processed image, with the original image presented first and the processed image next in the described workflow.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Standalone deep-learning software connected to a local radiology network through a DICOM node and PACS; the processed image is returned as a DICOM image for review.
AZmed describes the Rayvolve suite as radiology AI that can be integrated into clinical imaging workflows; the current page does not establish the exact hosting, service levels or version for K243831.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-07Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission
No public price or quote for Rayvolve LN was reviewed.
Pricing model: Not verified - checked 2026-09-07 - Exact FDA submission
License, per-study, subscription and implementation terms were not established.
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "AZmed Rayvolve reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-07 - Exact FDA submission
The reviewed sources do not establish exact-release security controls, retention or assurance documentation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.
Authorized purpose: Passive triage of adult AP chest radiographs for an endotracheal-tube tip more than 7 cm above the carina, less than 3 cm above the carina, below the carina in the right or left mainstem, or other listed malposition states.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.